BRIM BiotechnologyTPE:6885 -0.46%40 PS Ratio is 530.49 as of Jul. 06, 2026, which is 94% below its 10-year median of 8,664.59. GuruFocus rates TPE:6885 with a GF Score™ of 40/100 and a GF Value™ of NT$486.91 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 929 Biotechnology companies, BRIM Biotechnology ranks worse than 93.65% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, BRIM Biotechnology's share price is NT$21.75.
BRIM Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.04. Hence, BRIM Biotechnology's PS Ratio for today is 530.49.
Good Sign:
BRIM Biotechnology Inc stock PS Ratio (=520.24) is close to 3-year low of 504.88.
The historical rank and industry rank for BRIM Biotechnology's PS Ratio or its related term are showing as below:
TPE:6885'
s PS Ratio Range Over the Past 10 Years
Min: 504.88 Med: 8664.59 Max: 47850
Current: 530.49
During the past 7 years, BRIM Biotechnology's highest PS Ratio was 47850.00. The lowest was 504.88. And the median was 8664.59.
TPE:6885's PS Ratio is ranked worse than 93.65% of 929
companies
in the Biotechnology industry
Industry Median: 9.91
vs TPE:6885: 530.49
BRIM Biotechnology Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of BRIM Biotechnology was 1300.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 81.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -45.90% per year.
During the past 7 years, BRIM Biotechnology's highest 3-Year average Revenue per Share Growth Rate was 81.70% per year. The lowest was -91.00% per year. And the median was -20.60% per year.
Back to Basics: PS Ratio
BRIM Biotechnology (TPE:6885) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
BRIM Biotechnology PS Ratio Related Terms
BRIM Biotechnology PS Ratio Historical Data
* Premium members only.
The historical data trend for BRIM Biotechnology's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BRIM Biotechnology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRIM Biotechnology PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BRIM Biotechnology's PS Ratio distribution charts can be found below:
* The bar in red indicates where BRIM Biotechnology's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
BRIM Biotechnology's Share Price of today is NT$21.75. BRIM Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
BRIM Biotechnology (TPE:6885) has a PS Ratio of 530.49 as of Jul. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BRIM Biotechnology and its competitors. This is 94% below median its historical median of 8,664.59. Over the past decade, BRIM Biotechnology's PS Ratio has ranged from 504.88 to 47,850.00. According to the industry distribution chart, BRIM Biotechnology ranks #870 out of 929 companies in the Biotechnology industry, placing it in the top 93.6%.
Is BRIM Biotechnology's PS Ratio too high?
BRIM Biotechnology's current PS Ratio of 530.49 is 94% below median its 10-year median of 8,664.59. Over the past 10 years, this metric has ranged from a low of 504.88 to a high of 47,850.00. The Biotechnology industry median PS Ratio is 9.91. BRIM Biotechnology's value of 530.49 is 5253.1% above this industry median. Based on the distribution chart, BRIM Biotechnology ranks #870 out of 929 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BRIM Biotechnology has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BRIM Biotechnology's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BRIM Biotechnology ranks #870 out of 929 companies for PS Ratio. This places BRIM Biotechnology in the lower half of its industry. The industry median PS Ratio is 9.91. BRIM Biotechnology's value of 530.49 is 5253.1% above this benchmark. Historically, BRIM Biotechnology's own PS Ratio has ranged from 504.88 to 47,850.00 over the past decade. While the company's 10-year median is 8,664.59 vs. the industry median of 9.91, BRIM Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.91, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BRIM Biotechnology's current PS Ratio of 530.49 is 5253.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BRIM Biotechnology and its competitors. For the Biotechnology industry, the median PS Ratio is 9.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRIM Biotechnology's current PS Ratio is 530.49, which is 94% below median its own 10-year median of 8,664.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRIM Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, BRIM Biotechnology (TPE:6885) is currently considered Possible Value Trap. The stock's GF Value™ is NT$486.91, compared to a current price of NT$21.75 — trading 95.5% below its estimated fair value. The current PS Ratio is 530.49, which is 94% below median its 10-year median of 8,664.59 and 5253.1% above the Biotechnology industry median of 9.91. BRIM Biotechnology's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For BRIM Biotechnology (TPE:6885), the current PS Ratio is 530.49 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRIM Biotechnology (TPE:6885) Overvalued in 2026?
Based on GuruFocus' analysis, BRIM Biotechnology stock appears to be undervalued.
The current stock price of NT$21.75 is trading 95.5% below its estimated GF Value™ of NT$486.91.
GuruFocus considers BRIM Biotechnology to be Possible Value Trap.
Key valuation signals for TPE:6885:
PS Ratio: 530.49 (94% below median its 10-year median of 8,664.59)
GF Value™: NT$486.91 vs. price of NT$21.75 (95.5% below fair value)
Industry Position: 5253.1% above the Biotechnology median (#870 of 929)
No single metric tells the full story. See the TPE:6885 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRIM Biotechnology Inc is engaged in the research and development of new drug translation, genetic testing services, research and development services in natural and engineering sciences, and medical laboratory services. The Group has two reportable operating segments: BRIM's main business is new drug translational development services, and Compass's main business is gene sequencing and testing technology services. It generates the majority of its revenue from the BRIM segment. Geographically, it operates in Taiwan, Japan, and the USA. It generates the majority of its revenue from Taiwan.
40GF Score
Get the complete analysis for TPE:6885
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6885 has been successfully added to your 
